The company has developed a biomarker-driven companion diagnostics platform that identifies the most suitable treatment for a cancer patient, preventing relapse and toxicity. Oncoassign's companion diagnostics are based on biomarkers discovered and validated on thousands of clinical patient samples, providing accurate predictions for the most beneficial treatment. With three co-founders and over 12 years of experience in AI and oncology, Oncoassign is a personalised medicine start-up that enables oncologists to predict the right treatment for a patient's specific cancer using a clinic-driven approach.